Abeona Therapeutics Inc. was a big mover last session, as the company saw its shares rise around 6% on the day. Shares gained after the company announced encouraging data from its ongoing Phase I/II trial for ABO-102, a single treatment gene therapy strategy for patients with Sanfilippo syndrome type A. The news led to far more shares changing hands than in a normal session resulting in solid volume. This continues the recent uptrend for the company as the stock is now up 23.1% in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Abeona Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.

A better-ranked stock in the same industry is Agenus Inc. (AGEN Quick QuoteAGEN - Free Report) , sporting a Zacks Rank #1 (Strong Buy).

Is ABEO going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>